The most distant part, overlapping the area where alternative splicing is presumed to occur, in the middle of the large exon of SSTR5 and the putative NAT promoter, was significantly less methylated in somatotropinomas than in NP. Here, SSTR5 is linked to growth hormone-producing pituitary gland neoplasm.